Your browser is no longer supported. Please, upgrade your browser.
DEPO Depomed, Inc. daily Stock Chart
Depomed, Inc.
Index- P/E- EPS (ttm)-1.22 Insider Own0.40% Shs Outstand61.80M Perf Week-3.43%
Market Cap1.43B Forward P/E15.42 EPS next Y1.50 Insider Trans-23.88% Shs Float60.66M Perf Month-5.75%
Income-73.90M PEG- EPS next Q0.36 Inst Own- Short Float22.56% Perf Quarter21.88%
Sales437.50M P/S3.27 EPS this Y-161.40% Inst Trans-0.35% Short Ratio9.82 Perf Half Y33.03%
Book/sh4.86 P/B4.76 EPS next Y26.39% ROA-5.60% Target Price26.58 Perf Year28.80%
Cash/sh1.90 P/C12.14 EPS next 5Y19.00% ROE-23.60% 52W Range12.25 - 27.02 Perf YTD27.52%
Dividend- P/FCF12.39 EPS past 5Y78.69% ROI-0.30% 52W High-16.25% Beta1.45
Dividend %- Quick Ratio1.00 Sales past 5Y33.50% Gross Margin80.20% 52W Low84.73% ATR0.79
Employees494 Current Ratio1.10 Sales Q/Q23.50% Oper. Margin-4.10% RSI (14)40.71 Volatility2.41% 3.68%
OptionableYes Debt/Eq0.00 EPS Q/Q52.30% Profit Margin-16.90% Rel Volume0.63 Prev Close23.12
ShortableYes LT Debt/Eq2.43 EarningsNov 02 AMC Payout- Avg Volume1.39M Price22.63
Recom2.30 SMA20-7.42% SMA50-1.68% SMA20019.62% Volume783,394 Change-2.12%
Oct-04-16Downgrade Mizuho Buy → Neutral $27
Sep-19-16Reiterated Mizuho Buy $23 → $27
Jul-27-16Downgrade Piper Jaffray Overweight → Neutral
Jul-07-16Downgrade UBS Buy → Neutral $20
May-27-16Reiterated Mizuho Buy $19 → $23
May-09-16Upgrade Mizuho Neutral → Buy $19
Apr-11-16Reiterated Mizuho Neutral $14 → $18
Mar-24-16Reiterated Mizuho Neutral $16 → $14
Mar-24-16Initiated Northland Capital Outperform
Mar-10-16Initiated Leerink Partners Outperform $21
Feb-25-16Reiterated Mizuho Buy $19 → $16
Feb-24-16Reiterated WallachBeth Buy $33 → $27
Feb-23-16Reiterated RBC Capital Mkts Sector Perform $26 → $24
Feb-08-16Initiated Piper Jaffray Overweight
Jan-07-16Initiated Mizuho Neutral $19
Dec-03-15Resumed Morgan Stanley Equal-Weight $21
Nov-11-15Upgrade WallachBeth Hold → Buy $33
Nov-11-15Reiterated ROTH Capital Buy $21 → $24
Nov-04-15Initiated Cantor Fitzgerald Buy
Oct-21-15Reiterated RBC Capital Mkts Sector Perform $32 → $26
Oct-25-16 04:08PM  DEPOMED INC Files SEC form 8-K, Change in Directors or Principal Officers
Oct-19-16 05:52PM  East Bay drug maker wards off hedge fund challenge with a price at
06:03AM  DEPOMED INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Officers
Oct-18-16 10:54AM  Why Visa, Johnson and Johnson, Pfizer, and Two Other Stocks Are in Spotlight Today at Insider Monkey
10:45AM  Is Settling With an Activist Investor Supposed to Be Bad for Shareholders?
Oct-17-16 06:33PM  [$$] Depomed to Add Starboard Nominees at The Wall Street Journal
06:33PM  Depomed agrees temporary truce with Starboard in proxy fight
05:43PM  Starboard DepoMed Director Deal Bolsters Sale Prospects
04:50PM  Starboard drops its bid to oust Depomed's board
04:00PM  Depomed and Starboard Announce Settlement Agreement GlobeNewswire
Oct-07-16 04:33PM  DEPOMED INC Files SEC form 8-K, Change in Directors or Principal Officers
Oct-04-16 03:49PM  Drug Win for Depomed Could Be Hurdle for Starboard
05:37AM  DepoMed downgraded by Mizuho
Oct-02-16 08:01AM  Why Diamondback Energy, Depomed, Las Vegas Sands and More Are Trending at Insider Monkey
Oct-01-16 07:51PM  East Bay drug company thwarts generics' grab, but fight's not over at
Sep-30-16 05:40PM  [$$] Depomed Gets Favorable Nucynta Patent Decision at The Wall Street Journal
05:16PM  Depomed wins Nucynta patent dispute Reuters
04:56PM  Depomed gets favorable patent ruling; stock up 3% in extended trading at CNBC
04:39PM  Depomed fends off Allergan's attempt at generic painkiller at MarketWatch
04:15PM  Depomed (DEPO) Closed Higher on Favorable Patent Ruling
03:55PM  Depomed Prevails in NUCYNTA Franchise ANDA Litigation Providing Market Exclusivity Until December 2025 GlobeNewswire
Sep-22-16 03:40PM  How Much Could DepoMed Fetch in a Deal? at Motley Fool
11:09AM  Depomed Inc (DEPO): Starboard Value LP Schedules Special Meeting of Shareholders at Insider Monkey
Sep-20-16 09:59AM  Report: Depomed Is Attempting to Sell Itself at Investopedia
Sep-19-16 01:33PM  [$$] Depomed to Hold Nov. 15 Shareholder Meeting at The Wall Street Journal
11:34AM  Arbor and Purdue Seen as Likely Bidders for DepoMed
10:47AM  Heres Why These Five Stocks Are Trending on Monday at Insider Monkey
08:21AM  Starboard sets date for special meeting of Depomed shareholders Reuters
07:59AM  Starboard delivers special shareholder meeting request to Depomed at MarketWatch
07:45AM  Starboard Delivers Special Meeting Request to Depomed and Issues Letter to Depomed Shareholders PR Newswire
Sep-16-16 06:23PM  Why Avis Budget Group, Depomed, and Community Health Systems Jumped Today at Motley Fool +14.60%
05:17PM  Depomed Receives Request to Call Special Meeting of Shareholders GlobeNewswire
04:07PM  Stocks End Volatile Week With Fed Meeting in Focus
01:13PM  Why DepoMed's Shares Are Jumping 12% Today at Motley Fool
12:19PM  Stocks Hold Lower as Crude Oil Slides
11:25AM  40 Trading Lessons from The PlayBook
11:25AM  Calls look for more gains in Depomed
10:27AM  Depomed (DEPO) Stock Soars Amid Sale Speculation
09:27AM  Depomed Inc (DEPO), Oracle Corporation (ORCL) & More: Why These Stocks Are Making Headlines at Insider Monkey
08:58AM  The Market In 5 Minutes: A Down Week Comes To A Close
Sep-15-16 06:08PM  DepoMed shares jump on report drugmaker preparing sale at MarketWatch
Sep-13-16 02:55PM  More Rare Disease Dealmaking to Follow Horizon's Raptor Deal
11:04AM  GSK Optimistic about Future of Its Consumer Healthcare Segment
Sep-12-16 03:55PM  Activist Starboard demands rapid changes at Perrigo
Sep-08-16 01:22PM  Nektar And Three Other Momentum Stocks With Bullish Charts at Forbes
11:57AM  4 Breakout Stocks to Watch
08:00AM  Data from Depomeds Highly-Differentiated Pain and CNS-Focused Product Portfolio Presented at PAINWeek 2016 GlobeNewswire
Sep-07-16 08:00AM  Depomed to Present at the Morgan Stanley Global Healthcare Conference GlobeNewswire
Sep-06-16 08:00AM  Depomed Announces Presentations at PAINWeek 2016 GlobeNewswire
Aug-29-16 11:18AM  ETFs with exposure to Depomed, Inc. : August 29, 2016
Aug-26-16 08:16AM  Depomed, Inc. breached its 50 day moving average in a Bearish Manner : DEPO-US : August 26, 2016
Aug-17-16 01:21PM  Infoblox, Depomed, Insperity: Inside Starboard Values 5 Biggest Moves of Q2 at Insider Monkey
Aug-16-16 06:31PM  Why a hedge fund wants this East Bay drug company to run like Olive Garden at
Aug-12-16 10:30AM  Depomed, Inc. :DEPO-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016
Aug-11-16 01:04PM  DEPOMED INC Financials
Aug-10-16 12:36PM  5 stocks to watch at MarketWatch
05:50AM  [$$] Drugmakers hooked on $10bn opioid habit at Financial Times
Aug-08-16 02:03PM  ETFs with exposure to Depomed, Inc. : August 8, 2016
Aug-05-16 08:08AM  Depomed, Inc. breached its 50 day moving average in a Bullish Manner : DEPO-US : August 5, 2016
Aug-04-16 01:22AM  Edited Transcript of DEPO earnings conference call or presentation 3-Aug-16 8:30pm GMT
Aug-03-16 05:35PM  Depomed reports 2Q loss
04:30PM  Depomed Inc Earnings Call scheduled for 4:30 pm ET today
04:09PM  DEPOMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:01PM  Depomed Reports Second Quarter 2016 Financial Results GlobeNewswire
09:05AM  GlaxoSmithKlines Consumer Healthcare Grows in 2Q16
07:07AM  Q2 2016 Depomed Inc Earnings Release - After Market Close
Jul-27-16 04:05PM  Depomed to Report Second Quarter Fiscal Year 2016 Financial Results on Wednesday, August 3, 2016 GlobeNewswire
Jul-26-16 09:13AM  Starboard Delivers Letter To Depomed Shareholders PR Newswire
Jul-18-16 01:34PM  Depomed Announces Patent Trial and Appeal Board Denial of Inter Partes Review of NUCYNTA Patent PR Newswire
Jul-15-16 09:05AM  Coverage Initiated on Select Drug Manufacturer Stocks
Jul-07-16 04:24PM  Depomed Downgraded On Weakness In Base Business, Stock Run-Up -8.71%
Jul-06-16 08:00AM  Depomed to Present at the Cantor Fitzgerald Healthcare Conference GlobeNewswire
Jun-28-16 08:33AM  Depomed, Inc. breached its 50 day moving average in a Bearish Manner : DEPO-US : June 28, 2016 +5.95%
Jun-24-16 09:45AM  Depomed to call special meeting of shareholders on Oct 28
06:03AM  DEPOMED INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Jun-23-16 04:05PM  Depomed Proposes to Call Special Meeting of Shareholders on October 28, 2016 Following Outcome of NUCYNTA Patent Litigation GlobeNewswire
Jun-14-16 04:00PM  Depomed to Present at the JMP Securities Life Sciences Conference GlobeNewswire
09:07AM  Featured Research Report on Drug Manufacturers Stocks
Jun-02-16 09:30AM  RIMA Senvest Grows Even More Bullish On Top Holdings at Insider Monkey
May-26-16 12:42PM  [$$] Starboard Calls for Depomed Board Overhaul at The Wall Street Journal
12:26PM  Starboard seeks Depomed special shareholder meeting
11:17AM  Depomed Issues Statement in Response to Starboards Press Release GlobeNewswire
10:03AM  Starboard calls for overhaul of Depomed board at MarketWatch
09:52AM  StarBoard requests Depomed special shareholder meeting Reuters
09:08AM  Starboard Delivers Letter to Depomed Shareholders PR Newswire
May-25-16 08:55AM  Top Analyst Upgrades and Downgrades: Applied Materials, Best Buy, Nokia, CSC, HPE, Monsanto, Noble Energy, Western Digital and More at 24/7 Wall St.
May-23-16 08:05AM  10 Speculative Biotech and Biohealth Stocks With Massive Analyst Upside Calls at 24/7 Wall St.
08:00AM  Cebranopadol Data Presented at World Institute of Pain Congress Highlight Clinically Significant Reductions in Pain, Low Abuse Deterrent Potential and a Favorable Respiratory Profile GlobeNewswire
May-20-16 04:28PM  DEPOMED INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other Events
May-18-16 04:45PM  Depomed Announces District Court Order Extending Stay in NUCYNTA ANDA Litigation GlobeNewswire
May-16-16 08:00AM  Depomed Announces Presentation of Cebranopadol Data at World Institute of Pain Congress GlobeNewswire
May-10-16 07:08PM  IBB: Makes Small Comeback Following a Tumble Last Week
06:00AM  'Mad Money' Lightning Round: I'm Sticking With at TheStreet
May-09-16 05:30PM  Horizon Pharma Spikes On Earnings Beat; Depomed Rises On Upgrade +15.09%
05:30PM  Horizon Pharma Spikes On Earnings Beat; Depomed Rises On Upgrade at Investor's Business Daily
03:23PM  Wall Street struggles for gains as crude falls Yahoo Finance
02:58PM  Why These Five Stocks Are in Spotlight Today? at Insider Monkey
10:49AM  Depomed, Inc. :DEPO-US: Earnings Analysis: Q1, 2016 By the Numbers
07:58AM  Early movers: HCP, LC, TSN, LUV, TEVA, BRKB, DIS TWTR, FB & more at CNBC
07:58AM  Early movers: HCP, LC, TSN, LUV, TEVA, BRKB, DIS TWTR, FB & more at CNBC
Depomed, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults; and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults. The company also provides NUCYNTA ER (tapentadol extended release tablets), a product for the management of pain severe enough to long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults; and NUCYNTA (tapentadol), a product for the management of moderate to severe acute pain in adults. In addition, it is involved in the clinical development of IW-3718 refractory gastroesophageal reflux disease program using Acuform drug delivery technology; and Cebranopadol, a molecule for the treatment of chronic nociceptive and neuropathic pain. Depomed, Inc. sells its Gralise products to wholesalers and retail pharmacies. The company also has a portfolio of license agreements based on its proprietary Acuform gastroretentive drug delivery technology with Mallinckrodt Inc.; Ironwood Pharmaceuticals, Inc.; and Janssen Pharmaceuticals, Inc. The company was founded in 1995 and is headquartered in Newark, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Vargas Thadd MSenior VP, BDSep 21Sale25.0011,250281,25073,086Sep 22 06:11 PM
Moretti August JChief Financial Officer & SVPAug 10Option Exercise12.693,29741,83924,977Aug 11 05:01 PM
Moretti August JChief Financial Officer & SVPAug 10Sale21.405,000107,00021,680Aug 11 05:01 PM
Vargas Thadd MSenior VP, BDAug 10Sale20.9226,290549,98784,336Aug 11 04:56 PM
Vargas Thadd MSenior VP, BDMay 23Sale20.0015,000300,000109,297May 25 04:46 PM
Vargas Thadd MSenior VP, BDMay 10Sale17.6415,000264,600124,297May 10 05:14 PM
Moretti August JChief Financial Officer & SVPMay 09Sale18.005,00090,00022,879May 09 04:48 PM
Schoeneck James APresident and CEOMar 18Option Exercise3.9430,483120,09436,848Mar 21 04:17 PM
Vargas Thadd MSenior VP, BDMar 11Sale16.0023,000368,000137,737Mar 11 06:40 PM
Vargas Thadd MSVP, Business DevelopmentMar 02Sale15.1810,000151,780160,737Mar 04 08:28 PM
Vargas Thadd MSVP, Business DevelopmentJan 11Option Exercise7.1218,180129,442170,737Jan 12 07:10 PM
Schoeneck James APresident and CEODec 28Option Exercise6.116,36538,8906,365Dec 28 07:24 PM
Moretti August JChief Financial Officer & SVPDec 16Option Exercise5.355,00026,75026,319Dec 17 12:31 PM
Moretti August JChief Financial Officer & SVPDec 03Sale18.1115,000271,59721,319Dec 03 06:32 PM